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Summary
The introduction of clotting factor concentrates has substan-
tially improved the lives of people with clotting factor defi-
ciencies. Unfortunately, the transmission of blood-borne viral
infections through these plasma-derived products led to a
huge epidemic of human immunodeficiency virus and viral
hepatitis in people with haemophilia (PWH). In a significant
proportion of PWH exposed to these viruses, the ensuing
decades-long chronic infection resulted in excess morbidity
and mortality. Fortunately, developments in the safety of
blood products, as well as vaccination and highly effective
antiviral treatments have improved the prospects of PWH.
The present article reviews the background of the viral hep-
atitis epidemic in PWH, the natural history of hepatitis B
and C infections and their long-term management.
Keywords: hepatitis C, HCV, HBV, haemophilia, HIV.
Treatment of haemophilia
Haemophilia A and B are inherited X-linked bleeding disor-
ders due to deficiency of factor VIII (FVIII) and factor IX
(FIX) respectively. The mainstay of their treatment is
through infusion of the missing clotting factor. Initial meth-
ods of replacement were poor and inefficient, involving
transfusion of fresh blood or fresh frozen plasma (FFP),
products that contain all the clotting factors in a dilute for-
mat. A major advance in FVIII replacement was the discov-
ery that cryoprecipitate contained FVIII in concentrated
form and was more efficient (in terms of volume) than FFP
in treating people with haemophilia A.1 However, problems
with cryoprecipitate use include the need to be given in hos-
pital, requirement for storage in a freezer, need for thawing
and a high likelihood of allergic reactions. Most of these lim-
itations were overcome by the introduction of plasma-
derived lyophilised FVIII and FIX concentrates in the 1970s.
This enabled the storage of the products in a domestic refrig-
erator, allowed full treatment in a small volume and made it
possible for patients to treat themselves at home, as well as
giving them the freedom to travel. In the 1990s recombinant
factor concentrates that did not use human plasma were
introduced and are the main form of concentrates in use in
Europe and North America today.2 However, in many parts
of the world plasma-derived concentrates still predominate
as the main form of treatment for people with haemophilia
(PWH).
Transfusion-transmitted infection
It has been recognised for >80 years that transfusion of
blood and blood products could be associated with transfu-
sion-transmitted infection (TTI).3 This remained a relatively
small issue until products from multiple donors were pooled
and started to be infused in recipients. In the late 1960s,
reports of jaundice started appearing after cryoprecipitate use
in PWH. The frequency of post-transfusion hepatitis
increased in the 1970s and it was recognised that, whilst
many cases were due to hepatitis B, another infective agent
termed non-A, non-B hepatitis (NANBH) was involved. In
the early 1980s, it became clear that the majority of PWH
exposed to pooled plasma-derived concentrates were infected
with NANBH, although its significance was uncertain. At
around the same time the human immunodeficiency virus
(HIV) became recognised as a major cause of TTI. Transfu-
sion-related NANBH was shown in the early 1990s to be
almost exclusively due to hepatitis C virus (HCV).4
Although HIV and HCV are the most well-known transfu-
sion transmitted viruses, many others have been reported.
PWH are susceptible to infection through their plasma-
derived FVIII or FIX concentrate treatment only with viruses
that can be found in plasma; they are no more susceptible
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than the general population to cell-associated viruses such as
the cytomegalovirus, Epstein–Barr virus and several human
herpes viruses, which have leucocytes as their mode of trans-
mission.5
Viral hepatitis and HIV in haemophilia
The risk of viral hepatitis and HIV transmission was very
small with products produced from single donations such as
red cells, platelets, FFP or cryoprecipitate. Notably, treatment
of a bleeding episode would often require multiple infusions
over several days. Furthermore, a single cryoprecipitate treat-
ment required multiple units of cryoprecipitate. Nonetheless,
the total number of required individual donations per bleed-
ing episode was still relatively low for these therapies. The
major move to treat PWH with lyophilised pooled plasma
concentrates changed all that, as the pools of plasma used
for fractionation could contain tens of thousands of individ-
ual donations. The level of viraemia in HCV- and HIV-in-
fected individuals is very high and, as no natural immunity
existed; most batches of FVIII/FIX were infected with HCV
and some with HIV as well. The infectivity of specific batches
depended on the plasma source and those relying on volun-
teer European donors were less infectious (especially for
HIV) than batches made by USA manufacturers who col-
lected blood from paid donors using plasma collection facili-
ties sometimes located in prisons or in deprived areas.6
The rates of HIV/hepatitis B virus (HBV)/HCV infections
in the haemophilic population varied depending on availabil-
ity and use of cryoprecipitate versus lyophilised plasma-
derived concentrate and the use of commercial American
plasma sourced products versus volunteer donor sourced
domestic manufacturing.7,8 In contrast to many countries,
only 1% of Finnish PWH (two of 213) tested positive for
HIV antibodies between 1985 and 1989.9 This is likely due to
the self-sufficiency for the production of clotting factors of
Finland and the low HIV prevalence in the Finnish popula-
tion at the time. However, even in Finland, 94% of patients
with severe haemophilia A, aged >20 years and treated with
locally produced lyophilised concentrates from unpaid blood
donations were anti-HCV positive in 1999,10 demonstrating
that in contrast to HIV, the pooling of large numbers of
plasma donations resulted in high pool infectivity. In the
Netherlands, 99% of those treated with non-viral inactivated
large pool concentrates were anti-HCV positive, compared to
66% of those treated with cryoprecipitate.11 A comparison
between Scottish PWH who received locally produced factor
concentrates and Danish PWH who received both local and
American factor concentrates, reported HCV antibody preva-
lence of 16% and 59% respectively.12 In Sweden, where both
American and Swedish factor concentrates were used, HIV-
positive persons with haemophilia A received significantly
more American concentrate.13 Countries with poor access to
concentrates have had low levels of viral infections in their
PWH.
The pooling of donations was key to the infectivity of
concentrates. Whereas pools produced from plasma dona-
tions usually included up to 10 000 donors, plasma obtained
from whole blood donations could contain plasma from as
many as 60 000 donors.14 The impact of the size of the
plasma pool on final infectivity is debated. A modelling study
from 1996 showed that the risk of exposure to infectious
agents for patients requiring repeated treatments, such as
PWH, would only have been minimally affected by large
reductions in pool size.14
Another issue that reduced the prevalence of infections in
persons with mild haemophilia A, was the use of desmo-
pressin that induces the endogenous release of FVIII, which
can be sufficient for many treatments.15
The introduction of viral inactivation
The infection of many PWH with HIV led to the introduc-
tion of viral inactivation of concentrates in late 1983 and
early 1984. The early virally inactivated concentrates were
safe in terms of viral transmission when infused into chim-
panzees, and although infectivity was reduced especially for
HIV, some NANBH infections still occurred in PWH. The
later viral inactivation procedures employing higher temper-
ature, wet heat, pressure and chemicals were much more
effective in eliminating hepatitis and HIV infectivity from
concentrates.16 Viral transmission was further reduced/elimi-
nated due to the combination of viral inactivation and viral
exclusion. Viral exclusion has been achieved through chro-
matographic and immunoaffinity protein purification tech-
niques applied to high purity concentrates, and dedicated
steps such as wet and dry heating, solvent/detergent treat-
ment, and nanofiltration. Finally, procedures such as defer-
ral of donors with risk factors for HIV infection, as well as
serological and nucleic acid amplification testing of pooled
donations, were introduced to reduce the risk of TTI.
Although viral inactivation was highly effective against HIV
and HCV, some PWH treated with FVIII in the early 1990s
in Europe, the USA and South Africa were infected with
hepatitis A virus (HAV), a virus normally transmitted via
the faecal–oral route.17 The reason for this, turned out to
be poor efficacy of the viral inactivation processes used at
the time against lipid enveloped viruses such as HAV.17
This resulted in the regulatory authorities recommending
that all clotting factor concentrates should undergo two
separate viral inactivation steps, a recommendation that is
still in use today.18
Other concerns related to viral inactivation were the
potential adverse effects of the inactivation steps. In particu-
lar, this concerned potential immunogenicity of inactivated
products, resulting in alloantibodies against administered
clotting factors. In Belgium and in the Netherlands, increased
incidence of FVIII alloantibodies (inhibitors) was linked to
the introduction of new FVIII products virally inactivated
through pasteurisation.19,20 Fortunately, inhibitors
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disappeared after switching product. Nonetheless, these
occurrences served as a warning for the potential risks of
adaptations in production or viral inactivation methods.
Potential infectivity of current plasma-derived
concentrates
Undoubtedly, the current plasma-derived concentrates are
the safest they have ever been. The possibility of infection
with HIV and HCV is theoretical as the measures instituted
by manufacturers will not only prevent infected donors from
donating, but the purification process in combination with
viral inactivation processes are highly efficient in reducing
and inactivating HIV and HCV.16
Transmission of other viruses remains possible on rare
occasions. Parvovirus B19 causes a childhood illness called
fifth disease and has been shown to be still transmissible by
concentrates because none of the current viral inactivation
steps can destroy it completely.21 Another group of infective
agents that cannot be destroyed by currently used viral inac-
tivation procedures are prions such as classical and variant
Creutzfeld–Jacob Disease (vCJD). Although many PWH have
been exposed to plasma products made from donors who
went on to develop vCJD, no patient with an inherited
bleeding disorder has ever developed symptoms of vCJD.
However, one PWH who died from an unrelated cause and
received treatment with plasma-derived FVIII and non-leu-
codepleted red cells was found to have prions in his spleen
at autopsy.22
The natural history of HCV infection in
haemophilia
Studying the natural course of HCV infection is often limited
by unknown dates of infection and inconsistent follow-up.
However, for PWH the onset of the infection can be reason-
ably traced back to the first clotting factor concentrate infu-
sion.23 Furthermore, in many countries all PWH have been
systematically tested for HCV infection, decreasing the risk
of selection bias that occurs when patients are tested only
once they develop symptoms or signs of chronic hepatitis.
Finally, PWH are reviewed regularly at their haemophilia
treatment centre, providing reliable follow-up data indepen-
dent of HCV status. Therefore, PWH are a good population
in which to study the natural history of HCV infection.
Acute HCV infection is asymptomatic in most cases and
therefore was rarely recognised in PWH during the HCV epi-
demic. The proportion of HCV-infected PWH in whom the
infection did not progress to chronic HCV varies in different
reports from 7% to 23%,24–31 of which most estimates range
between 10% and 20%.24–28,31 These percentages of sponta-
neous clearance are slightly lower than the average 26% spon-
taneous clearance rate in other HCV populations.32 Likely, this
is due to the relatively high number of HIV co-infected PWH,
which is known to significantly decrease the chance of
spontaneous clearance.24,33,34 In those in whom the HCV infec-
tion progressed to a chronic infection, the most common
HCV genotypes were genotype 1 (65–70%), followed by geno-
type 3 and 2 with 15–20% and 10–15% respectively.24–27,30,31
Chronic HCV infection can lead to the development of
liver fibrosis and eventually cirrhosis. The ‘gold standard’ for
diagnosis of liver fibrosis and cirrhosis is liver biopsy. The
main study describing liver biopsy results in PWH is a series
of 220 liver biopsies from a cohort of 781 HCV-positive
PWH.35 Advanced fibrosis or cirrhosis (Metavir fibrosis
scores of ≥F3) was seen in 52 (24%), with a slightly higher
mean fibrosis score in HIV-infected PWH.35 It is known that
HIV infection accelerates HCV-related liver fibrosis progres-
sion.36 As liver biopsy is an invasive procedure with adherent
risk of complications such as bleeding and therefore not rou-
tinely performed, potential confounding by indication is
important to consider in interpreting these results.
More often than liver biopsy results, non-invasive liver
stiffness measurements using transient elastography (TE) are
reported as an indicator of liver fibrosis and cirrhosis in
PWH (Table I).37–42 In these studies, 40–50% of PWH had
no or minimal fibrosis (F0–F1) after an infection duration of
≥20 years.37–39 Severe fibrosis or cirrhosis (F3 or F4) was
found in 30–35% of PWH.37–40 These rates of progression to
severe fibrosis and cirrhosis are comparable to those found
in studies from the general population.41,42 An important
consideration when considering TE results, is that several fac-
tors can lead to false-positive elevated values, as explained
below. Furthermore, selection bias is likely, as many HIV/
HCV co-infected PWH already died because of opportunistic
infections by the time TE became available.
Several studies describing the natural history of HCV-in-
fected PWH have focussed on the occurrence of end-stage
liver disease (ESLD), which in these studies is usually defined
as the occurrence of decompensated cirrhosis, bleeding oeso-
phageal varices, hepatocellular carcinoma (HCC) or liver-re-
lated death. In three cohorts with ≥30 years of follow-up
since HCV infection, the cumulative incidence of ESLD was
between 10% and 15%.24,28,29 The largest of these three
cohorts was a multicentre study conducted by our group
from the Netherlands and the UK, which included 863 HCV-
seropositive patients with a median infection duration of
31 years.24 Co-infection with HIV was present in 212 (25%)
of the patients, whereas co-infection with HBV was uncom-
mon with only 16 hepatitis B surface antigen (HBsAg)-posi-
tive patients (2%). Of the 700 HCV-infected patients who
developed chronic HCV, ESLD based on the criteria men-
tioned above occurred in 90 (13%) after a median infection
duration of 23 years.24 This rate was slightly higher in the
group of 510 HCV patients without successful antiviral treat-
ment, of whom 88 (17%) developed ESLD. The all-cause
mortality at the end of follow-up was 28%, of which 28%
was liver-related, being the second cause of death after HIV/
acquired immune deficiency syndrome (AIDS) (32%).24 The
largest cohort in which progression of HCV infection to
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ESLD in PWH was evaluated is an American and European
collaboration of 16 centres from 2002.43 In this study, 1818
HCV-seropositive PWH were included with a relatively short
median follow-up of 12 years. At the end of follow-up, 137
(8%) participants developed ESLD based on the criteria
mentioned above, of which only two cases were HCC.43
An important risk factor for both progression of liver
fibrosis and occurrence of ESLD in HCV-infected PWH is
HIV co-infection. Although in recent years safer and less
hepatotoxic antiretroviral therapy has resulted in a more
similar progression of liver fibrosis in HIV/HCV co-infected
patients,44 virtually all co-infected PWH have been infected
for ≥30 years, before these new treatment modalities became
available. As a result, HIV co-infected PWH not only have
higher fibrosis scores, but also account for the majority of
ESLD cases.24,26,28,35,37,43 The large haemophilia cohort study
from 2002 reported 127 ESLD cases in 1192 HIV-positive
PWH compared to only 10 in 624 HIV-negative PWH.43
Cumulative incidences of ESLD at 16 years of follow-up were
14% and 3% for HIV-positive and -negative HCV-infected
PWH respectively. Likewise, in the cohort of 863 HCV-in-
fected PWH with >30 years of follow-up, ESLD rates were
22% and 7% in HIV-positive and -negative HCV-infected
individuals respectively.24 In this cohort, HIV co-infection
was the strongest predictor of ESLD occurrence, with a haz-
ard rate of 11.24
Besides HIV, several other factors are associated with pro-
gression of liver disease and occurrence of ESLD in HCV-
positive PWH. The determinant most strongly associated
with a decreased risk of developing ESLD is successful HCV
antiviral treatment.24,26–28,30 Nonetheless, despite successful
treatment being a strong predictor of decreased ESLD risk,
HCC and decompensated cirrhosis still occur after sustained
virological response (SVR) or spontaneous clearance. This is
infrequent and is predominantly seen in patients with liver
cirrhosis before the start of HCV treatment or with other
liver-related risk factors such as obesity and alcohol
abuse.24,28 Other factors associated with development of liver
cirrhosis or ESLD are age at HCV infection,24,26,28 age in
general30,31,43 and HBsAg positivity.26,43
The use of antiviral therapy for HCV
The first clinical trial to treat NANBH in haemophilia with
interferon (IFN) injections commenced 2 years before the
discovery of HCV.45 In the following decade, the addition of
the oral antiviral drug ribavirin and later replacement of
standard IFN with PEGylated IFN (PEG-IFN) improved the
efficacy of HCV treatment. In 2006, we reviewed the publica-
tions on treatment of HCV in haemophilia and included 35
studies with 1151 PWH in the analysis.46 In treatment-naive
HIV-negative PWH, SVR rates were 22% for IFN monother-
apy, 43% for IFN with ribavirin and 57% for PEG-IFN with
ribavirin. In HIV/HCV co-infected PWH, SVR rates for IFN
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ribavirin was comparable to HIV-negative PWH at 39%.46
Subsequent studies evaluating PEG-IFN efficacy in HIV-posi-
tive PWH showed varying results, with the SVR rate ranging
from 8% to 50% (Table II).46–69
Treatment with PEG-IFN and ribavirin came at the cost
of significant side-effects. Moreover, these regimens were less
effective in HCV genotype 1 infections,48 the most common
genotype in HCV-infected PWH.24 The introduction of
direct-acting antivirals (DAA) drastically changed the land-
scape of HCV treatment. At first, so-called ‘triple therapy’
became available, in which the protease inhibitors, telaprevir
or boceprevir, were combined with PEG-IFN and ribavirin.
These regimens showed high SVR rates of 60–75% in treat-
ment-na€ıve patients with HCV genotype 1.70 Apart from sev-
eral case reports, no haemophilia-specific efficacy studies of
these first-generation DAA were published. In 2016, San-
tagostino et al.58 published a study in which 51 PWH were
treated with a combination of lambda-IFN, ribavirin and the
second-generation DAA daclatasvir (DAC), demonstrating
90% efficacy. However, despite its high efficacy this regimen
was never widely used, because IFN-free, all-oral DAA regi-
mens were introduced at around the same time. Current
DAA can be divided in three classes, all targeting different
parts of the viral genome responsible for replication. Besides
the NS3-4A serine protease inhibitors (-previr), these are
non-structural protein (NS)5A inhibitors (-asvir) and NS5B
inhibitors (-buvir). Combinations of these classes of inhibi-
tors result in SVR rates of >95%, in general within 2–
3 months of treatment.
Stedman et al.57 were the first to publish IFN-free DAA
results specifically for PWH. In their phase II trial published
in 2015, all 14 PWH infected with HCV genotype 1 and trea-
ted with sofosbuvir (SOF)/ledipasvir (LDV) achieved SVR-
12, defined as an undetectable viral load 12 weeks after
Table II. Overview of studies reporting HCV treatment efficacy in patients with inherited bleeding disorders.









Posthouwer et al., 200646 Review IFN monotherapy 434 22 (95/434) 51 8 (4/51)
IFN + Rbv 407 41 (165/407) 23 39 (9/23)
PEG-IFN + Rbv 168 57 (96/168) 0
Shire et al., 200647 Prospective PEG-IFN + Rbv 11 45 (5/11) 11 27 (3/11)
Posthouwer et al., 200748 Retrospective IFN monotherapy 101 29 (29/101) 35 20 (7/35)
IFN + Rbv 72 44 (32/72) 2 50 (1/2)
PEG-IFN + Rbv 62 63 (39/62) 23 48 (11/23)
Maor et al., 200849 Retrospective PEG-IFN + Rbv 37 46 (17/37) 5 20 (1/5)
Katsarou et al., 200851 Prospective PEG-IFN + Rbv 31 58 (18/31) 19 11 (2/19)
Denholm et al., 200950 Retrospective PEG-IFN + Rbv 0 13 8 (1/13)
Alavian et al., 201053 Prospective PEG-IFN + Rbv 367 61 (225/367) 0
Moghaddam et al., 201254 Prospective PEG-IFN + Rbv 45 96 (43/45) 0
Honda et al., 201355 Retrospective PEG-IFN + Rbv 23* 65 (15/23) *
Lin et al., 201456 Prospective PEG-IFN + Rbv 12 67 (8/12) 0
Yang et al., 201552 Retrospective PEG-IFN + Rbv 102 86 (88/102) 2 50 (1/2)
Stedman et al., 201557 Phase 2 trial SOF/LDV + Rbv 14 100 (14/14) 0
Santagostino et al., 201658 Phase 3 trial Lambda-IFN + Rbv + DAC 51 90 (46/51) 0
Ackens et al., 201659 Case report SOF/DAC 0 2, with ESLD 100 (2/2)
Walsh et al., 201760 Phase 2 trial SOF/LDV, SOF + Rbv 94 98 (92/94) 26 100 (26/26)
Hezode et al., 201761 Phase 3 trial EBR/GZR 101 94 (95/101) 6 83 (5/6)
Lee et al., 201762 Prospective SOF/LDV, SOF + Rbv
or DCV/ASV
30* 93 (28/30) *
Uemura et al., 201763 Prospective SOF/LDV, SOF + Rbv
or SOF/DAC
0 27 100 (27/27)
Wiegand et al., 201764 Retrospective Various DAA regimens 18 94 (17/18) 0
Mehta et al., 201765 Retrospective SOF/DCV 4 100 (4/4) 0
Nagao and Hanabusa 201766 Prospective SOF/LDV 23 100 (23/23) 20 95 (18/20)
Xiao et al., 201967 Retrospective Various DAA regimens 0 12 100 (12/12)
Mancuso et al., 202068 Prospective Various DAA regimens 160 100 (160/160) 40 95 (38/40)
Guedes et al., 202069 Retrospective Various DAA regimens 16* 100 (16/16) *
ASV, asunaprevir; DAA, direct-acting antiviral; DAC, daclatasvir; EBR, elbasvir; ESLD, end-stage liver disease; GZR, grazoprevir; HCV, hepatitis
C virus; IFN, interferon; LDV, ledipasvir; PEG-IFN, PEGylated interferon; Rbv, ribavirin; SOF, sofosbuvir; SVR, sustained virological response;
VEL, velpatasvir.
*Human immunodeficiency virus (HIV) status not reported.
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cessation of HCV treatment. Subsequently, in 2017, results
from four other DAA trials specifically for patients with
inherited bleeding disorders were published (Table II).60–63
In a USA multicentre trial, SOF/LDV was administered to
patients with genotype 1 or 4 and SOF plus ribavirin to
patients with genotype 2 and 3.60 The SVR-12 rate in the
120 included patients was 98% (118/120), due to one relapse
in a PWH with HCV genotype 3 infection and one being lost
to follow-up. In another trial, elbasvir/grazoprevir was given
to 47 patients with genotype 1 or 4 and either haemophilia
or von Willebrand disease, resulting in an 89% (42/47) SVR-
12 rate.61 In Korea, 30 PWH were treated with different regi-
mens, with a 93% SVR-12 rate due to two failures in geno-
type 1b patients receiving DAC/asunaprevir.62 The final DAA
trial in PWH was conducted in Japan, where 25 HCV/HIV
co-infected PWH also receiving different regimens were all
successfully treated.63
Besides these trials showing DAA to be highly effective in
HCV-infected PWH, they also demonstrated that the drugs
were generally well-tolerated and safe. Predominantly mild
side-effects were reported in 60–90% of treated patients,
being more frequent in those receiving ribavirin.57,60,61,63 The
most frequent side-effects were headache, fatigue and nausea,
occurring in 10–30% of patients. Importantly, drug-related
haemorrhage was very rare in these four trials, with only one
patient having an episode of epistaxis that was considered
drug-related.60 An exception to this low rate of serious
adverse events is seen in patients with decompensated Child–
Pugh B and C liver cirrhosis. After several reports of liver
failure and death following treatment with DAA regimens
containing a protease inhibitor (glecaprevir, grazoprevir, vox-
ilaprevir) there was a post-approval United States Food and
Drug Administration (FDA) safety warning71 that these drugs
should not be prescribed in patients with current Child–Pugh
B and C liver cirrhosis.
DAA efficacy has also been demonstrated in real-world
reports of usage including in PWH (Table II). The largest
study originates from Italy, in which 200 PWH were treated
with different DAA regimens.68 In this cohort, SVR-12 was
achieved in 99% (193/195) of patients, while no DAA-related
serious adverse events were seen. An SVR-12 rate of >94%
was also seen in all other published real-world studies
(Table I).59,64–66,68,69,72 This high DAA treatment efficacy
corresponds to efficacy rates seen in other HCV patients.
Slightly lower SVR rates, although in general still >90%, are
seen in patients with genotype 3 infection or cirrhosis, while
DAA treatment efficacy does not differ between HCV mono-
infected and HIV/HCV co-infected patients.73 The current
state of the art DAA are glecaprevir with pibrentasvir and
SOF with velpatasvir, generally prescribed for 8 and 12 weeks
respectively. These great advances in HCV treatment have
offered the perspective of HCV elimination within the hae-
mophilia population, with Slovenia being the first country to
actually report this milestone.74
The natural history of HBV infection in
haemophilia
The natural history of HBV is characterised by five different
phases (Table III).75 HBsAg is detectable in the first four
phases, which are mainly distinguished by the presence of
hepatitis B e antigen (HBeAg) and whether there are
increased transaminases as signs of hepatic inflammation.75,76
Antiviral treatment should in general be considered in
patients with prolonged HBeAg-positive or -negative hepati-
tis [as indicated by prolonged (>3 months) increased
transaminases] and in those with signs of advanced fibrosis
or cirrhosis. Current suppressive HBV treatment (entecavir,
tenofovirdisoproxil and tenofoviralafenamide) is very effec-
tive and with only limited risk of side-effects. Adequate HBV
DNA suppression is eventually achieved by >95% of treated
patients, thereby strongly reducing the incidence of cirrhosis,
ESLD and HCC.76 In absence of significant liver fibrosis,
HBsAg-positive PWH without current indication for antiviral
treatment should be monitored with at least 6 monthly ala-
nine aminotransferase (ALT) measurements, and should be
referred for consideration of antiviral treatment if ALT
increases above the upper limit of normal.75
The fifth phase of HBV infection, most common in PWH,
is the phase where serum HBsAg is negative and antibodies
Table III. Different phases of hepatitis B virus infection.
HBeAg positive* HBeAg negative*
HBsAg negativeChronic infection Chronic hepatitis Chronic infection Chronic hepatitis
HBsAg High High/intermediate Low Intermediate Negative
HBeAg Positive Positive Negative Negative Negative
HBV DNA >107 iu/ml 104–107 iu/ml <2000 iu/ml >2000 iu/ml Usually undetectable
ALT Normal Elevated Normal Elevated† Normal
Liver disease None/minimal Moderate/severe None Moderate/severe None
ALT, alanine aminotransferase; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus.
Table adapted from the European Association for the Study of the Liver (EASL) HBV guideline.75
*Therapy should particularly be considered in patients with persistent HBeAg-positive or -negative hepatitis and in patients with cirrhosis.
†Can be elevated persistently or intermittently.
Review
6 ª 2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
to hepatitis B core antigen (anti-HBc) and generally also
HBsAg (anti-HBs) are positive.75,76 Notably, patients who
become HBsAg negative do not completely resolve their
HBV infection, as they keep integrated covalently closed cir-
cular (ccc) HBV DNA in their hepatocytic DNA. Nonethe-
less, non-cirrhotic patients who achieve HBsAg
seroconversion have a minimal risk of developing cirrhosis in
the absence of co-factors.77 However, those who developed
cirrhosis remain at significant risk for HCC. An important
consideration for PWH ever infected with HBV, is the risk of
HBV flare or reactivation during chemotherapy or immuno-
suppression. In these patients prophylactic antiviral therapy
should be considered, depending on HBsAg status and sever-
ity of immune suppression.75,78 During DAA therapy for
HCV, HBsAg seroreversion should be monitored, although
this occurs infrequently (14% of DAA-treated patients).79
Literature on the natural history of HBV in PWH is
scarce. In recent studies aiming to find risk factors for ESLD,
HBV infection was not considered, probably due to its low
prevalence.24,27 In 2002, data from a large combined Ameri-
can and European cohort were published demonstrating a
hazard rate for development of ESLD in HIV/HCV co-in-
fected PWH of 8 for those with chronic HBV infection.43 As
discussed by the authors, an important note regarding these
numbers is that only 9% of HIV/HCV co-infected PWH in
the cohort were HBV unexposed, making the estimate of the
impact of HBV infection imprecise. Furthermore, the study
was published in a completely different antiviral treatment
era. Nonetheless, virtually all PWH infected with these
viruses were exposed before 1990, thus this study contains
the most representative data on the natural history of HBV
infection in PWH.43
In order to prevent HBV infection, all children and adults
without (previous) HAV or HBV infection and likely to
receive plasma-derived concentrates should have be offered
HAV and HBV vaccination. In PWH, subcutaneous adminis-
tration is recommended above intramuscular administration,
as it leads to comparable immunogenicity without the risk of
intramuscular haematoma.80,81
Hepatitis delta virus (HDV) is a defective virus that
requires the presence of HBsAgs to replicate. Already in
1982, it was reported in Italy that HBsAg-positive PWH were
at a high risk of HDV superinfection, with antibodies to the
delta virus found in 49% of HBsAg-positive adult PWH and
25% of HBsAg-positive children.82 Conversely, in Germany
anti-HDV was only found in 03% of HBsAg-positive blood
donors, compared to 50% again in PWH.83 HDV superinfec-
tion severely accelerates the rate of liver fibrosis progression,
as already recognised in 1985 when HDV superinfection was
found to be significantly more common in HBsAg-positive
PWH with fulminant liver disease than without.84 Due to the
low prevalence of HBsAg in PWH today, as well as the risk
of liver-related mortality in those infected with HDV long
ago, current HDV prevalence in PWH is likely low, although
definitive recent data are lacking. Recently a new promising
antiviral agent, bulevirtide, which blocks the entry of HBV
and HDV into hepatocytes, was conditionally approved by
the European Medicines Agency (EMA).85
Diagnosis, complications and therapeutic
considerations in cirrhosis
Although it has been demonstrated that (especially transjugu-
lar) liver biopsy can be performed relatively safely in PWH,86
staging of liver fibrosis is now usually determined with non-
invasive methods for which no clotting factor correction is
required. The most widely used laboratory-based tests in
patients with HCV are the aspartate aminotransferase (AST)
to platelet ratio (APRI) and Fibrosis-4 Index for liver fibrosis
(FIB-4).87,88 Both tests require only regularly collected labo-
ratory values and have demonstrated moderate to good accu-
racy. In a meta-analysis evaluating the accuracy of APRI in
patients with HCV, an APRI threshold of 10 had a 76% sen-
sitivity, 72% specificity, 55% positive predictive value (PPV)
and 69% negative predictive value (NPV) for predicting or
excluding cirrhosis.89 The accuracy of the FIB-4 Index was
evaluated in a series of 592 HCV-infected patients, showing a
74% sensitivity, 80% specificity and 95% NPV for excluding
severe fibrosis (<F3) at a FIB-4 value <145, and a 38% sensi-
tivity, 98% specificity and 82% PPV for predicting severe
fibrosis (≥F3) at a FIB-4 value >325.90
The most frequently used method to assess liver fibrosis at
present is TE using FibroScan. TE is valuable as it is cheap,
fast, and non-invasive and has excellent intra- and interob-
server variability.91 TE cut-off values for patients with HCV
are ≤70 kPa for F0–F1 (no or mild fibrosis); 71–94 kPa for
F2 (moderate fibrosis); 95–124 kPa for F3 (advanced fibro-
sis); and ≥125 kPa for F4 (cirrhosis).92 However, TE cannot
accurately distinguish F0/1 from F2 or F3 from F4. At a cut-
off value of 95, TE has 73–86% sensitivity, 85–91% specificity,
71–87% PPV and 81–93% NPV for the presence of advanced
fibrosis or cirrhosis (F3/F4).93,94 Importantly, several patient-
related factors can result in false-positive elevated TE values,
such as elevated transaminases, extra-hepatic cholestasis, right
decompensation from cardiac or pulmonary causes and (more
limited) non-fasting conditions.95 Of particular relevance is
that TE is quite unreliable in establishing fibrosis regression in
patients with HCV with previous F3/F4 fibrosis who have sus-
tained viral response after successful antiviral therapy. Addi-
tional liver biopsy often shows persistent cirrhosis in patients
with F0/1 or F2 fibrosis on TE.96,97 Therefore, patients with
radiological evidence of advanced liver disease or F3/F4 fibro-
sis according to TE before antiviral therapy should in general
remain in surveillance for HCC after SVR, even if TE suggests
regression of fibrosis after the antiviral therapy.
Radiological imaging is not very sensitive in diagnosis of
advanced liver disease. Although ultrasonography, computed
tomography and magnetic resonance imaging can detect
quite specific indications of advanced cirrhosis such as liver
nodularity or portal hypertension, their sensitivities and
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NPVs are low. Endoscopic surveillance for oesophageal
varices is in general recommended in cirrhotic patients with
a TE value ≥25 kPa and a platelet count <110 9 109 cells/l.98
Nevertheless, current insights allow a more restrictive follow-
up of surveillance after successful anti-HCV therapy in case
of cirrhotic patients without or with small stable varices in
absence of previous variceal bleeding or co-factors for pro-
gression of fibrosis.78 Treatment of symptoms of cirrhosis is
mainly limited to patients with signs of decompensated cir-
rhosis, such as hepatic encephalopathy, varices or ascites.
Furthermore, as malnutrition and sarcopenia are frequent
complications in patients with advanced liver disease, nutri-
tion guidelines recommend dietary counselling, sufficient
protein intake, late evening protein intake, and especially in
patients with ascites, a maximum daily sodium intake of
80 mmol.99
Hepatocellular carcinoma
Liver cancer, in 90% of cases caused by HCC, is the fifth
most prevalent and second most lethal type of cancer glob-
ally.100 Among PWH the impact of HCC is even greater, as
it is the most common type of cancer and both HCC inci-
dence and mortality in PWH are greater than in the general
population.101,102 Furthermore, HCC incidence in PWH has
been increasing in the recent decades, as was demonstrated
by a threefold increase in HCC prevalence between 1998 and
2014 in a large American analysis of hospital discharge
data.101 This increase was more pronounced, albeit not
reaching statistical significance, from the 17-fold increase in
non-haemophilic men during the same period.
An increase in HCC prevalence was also seen in the long-
term follow-up study of 700 PWH with chronic HCV.24 In
this study, HCC was diagnosed in 22 (3%) of patients after a
median infection duration of 29 years. Notably, nine (41%)
of these cases occurred in the last 6 years of the follow-up,
which lasted until 2012. HCC prevalence was even higher in
similar but smaller cohorts from Ireland, Sweden and Scot-
land, with respectively 9%, 6% and 5% incidence after
30 years of HCV infection.25,26,28 Most of these rates are
higher than in the general HCV population, where the 30-
year HCC risk is estimated to be between 1% and 3%.103 In
contrast to most reports, a large single-centre American
study of 222 PWH with chronic HCV, reported only one
(05%) HCC case, after a median of 28 years of HCV infec-
tion.29 Apart from treating the underlying viral hepatitis and
advising to avoid alcohol and being overweight, one could
advise reducing coffee consumption considering the negative
association of (caffeinated or decaffeinated) coffee (with
dose–response relationship up to three cups) and prevalence
of cirrhosis or HCC.104 Furthermore, 3-hydroxy-3-methylglu-
taryl coenzyme A reductase inhibitors (also known as statins)
are associated with a lower risk of cirrhosis and HCC in
patients with chronic liver disease.105
HCC surveillance is indicated for cirrhotic patients with
an annual HCC incidence of ≥15%.106 Therefore, all PWH
with cirrhosis should be offered HCC surveillance, unless
HCC treatment would not be indicated due to severe comor-
bidity or not possible because of decompensated cirrhosis
without the prospect of future liver transplantation, as in
decompensated cirrhosis palliative anti-tumour therapy or
resection are in general contraindicated. Due to potential
understaging with TE, the European Association for the
Study of the Liver (EASL) also recommends surveillance in
patients with chronic HCV infection and Stage F3 fibrosis.106
The goal of surveillance is detection of HCC at an early
stage, as late-stage HCC has limited treatment options and
poor survival. HCC surveillance is usually performed with 6-
monthly ultrasonography, with or without the biomarker
alpha-fetoprotein (AFP). Importantly, liver inflammation can
sometimes cause false-positive elevated AFP levels.106
Although successful HCV treatment strongly reduces the
risk of HCC development,107 patients with pre-treatment cir-
rhosis remain at risk.108 In a large American non-haemophi-
lic cohort, the annual HCC risks for cirrhotic patients after
SVR were 37% and 12% for patients with pre-SVR FIB-4
scores of > or < 325 respectively.108 HCC incidence in pre-
treatment non-cirrhotic patients was very low in this study.
The recently published EASL HCV guideline recommends
indefinite HCC surveillance for all successfully treated
patients with Metavir F3 or F4 fibrosis scores.73 As men-
tioned above, this should also be done when TE would sug-
gest regression of fibrosis post-SVR.
Various treatment options exist for HCC, although cura-
tive treatment options are mainly limited to liver transplan-
tation, resection and sometimes radiofrequency ablation
(RFA). Survival is most favourable in the selected group of
patients who are eligible for liver transplantation. Resection
leads to a 5-year survival rate of 60–80%.106 Unfortunately,
recurrence or de novo HCC are seen in 70% of patients after
resection or RFA.106,109 In case of advanced local growth or
extrahepatic spread, palliative anti-tumour treatment options
should be considered (e.g. percutaneous RFA/cryoablation,
transarterial chemoembolisation, selective internal radiation
therapy and sorafenib).106,109 There are few data on the
impact and prognosis of these treatment strategies for PWH
specifically, most of which are summarised in a review by
Meijer et al.109
Liver transplantation in haemophilia
Orthotopic liver transplantation (OLT) is a definitive treat-
ment option for patients with decompensated cirrhosis or
early stage HCC. The first liver transplant in a PWH was
reported in 1985.110 The transplanted liver is able to produce
all clotting factors, usually at a sufficient level within 48–
72 h post-transplant.111 As the concentration of produced
clotting factors remains stable during long-term follow-up,111
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an important benefit of OLT in haemophilia is the functional
cure of the bleeding disorder.
Several studies have compared OLT outcomes between
PWH and non-haemophilic liver transplant recipients,
although these are usually small and often lack long-term fol-
low-up data. Despite perioperative clotting factor replace-
ment, PWH undergoing OLT have been reported to have an
increased risk of bleeding complications when compared to
non-haemophiliacs.112 However, this does not result in sig-
nificant difference in in-hospital mortality between these
groups.112 Likewise, the post-transplant survival rates appears
similar between PWH and non-haemophiliacs.113,114 In vari-
ous studies, the post-transplant survival rate for PWH after
1, 3 and 5 years range between 78% and 90%, 67–80% and
54–67%, respectively.111,113–115 PWH undergoing OLT now
are likely to have an improved survival rate compared to
these historical cohorts. The most common cause of death
after OLT in these studies was liver failure due to recurrent
HCV or HCC,24,111,113 for which many new treatment
options have become available recently. In the general HCV
population, this has already resulted in increased post-trans-
plant survival in the DAA era.116
Liver disease in the upcoming era of new
haemophilia therapies
Recent developments in haemophilia treatment have included
gene therapy where the FVIII and FIX genes are inserted into
the liver cells, enabling sustainable production of clotting fac-
tors after a single viral vector administration.117 The most
widely used method for gene replacement in rare genetic dis-
eases employs adeno-associated virus (AAV) as the vector.
Although AAV has been considered to be a non-integrating
vector, it rarely does integrate to a small degree. Importantly,
when this low risk of integration is multiplied by the large
number of infused AAV vectors and large number of hepato-
cytes, AAV integration is inevitable and occurs with an esti-
mated frequency of one in 1000–10 000 hepatocytes.118 In
theory, AAV integration next to an oncogene in a fibrotic or
cirrhotic liver could lead to HCC development.
Recently, the discussion on whether this is an actual risk
of AAV gene therapy has become very relevant after a partic-
ipant of the UniQure AAV5-FVIII trial developed HCC
1 year after gene replacement therapy.119 This participant
had previously been successfully treated for HCV, had a
prior HBV infection and was reported to have evidence of
non-alcoholic fatty liver disease. At the time of writing,
tumour histology and sequence results are still awaited. Rul-
ing out involvement of AAV integration into the tumour
DNA will be crucial for the future of AAV gene therapy.
As a number of other new non-replacement treatments
are introduced for the treatment of haemophilia, clinicians
should be alert to the facts that the new therapies could
cause hepatic dysfunction or that a patient’s damaged liver
could impact the efficacy and safety of the therapy. We are
not aware of any evidence to suggest that the bispecific anti-
body, emicizumab, or the anti-tissue factor pathway inhibitor
(TFPI) therapies cause or are impacted by hepatic dysfunc-
tion. Pasi et al.120 reported that nine of 25 (36%) severe
PWH treated with the small interfering RNA (siRNA) mole-
cule Fitusiran developed elevated ALT levels, but these were
transient with no chronic sequelae.
Conclusion
The introduction of viral inactivation of plasma-derived concen-
trates, as well as the vaccination of patients against HAV and
HBV and the increasing use of recombinant products has practi-
cally eliminated new hepatitis viral infections in haemophilia.
For those already infected the use of DAA has made it possible
to clear the HCV from almost all the patients treated. Continued
monitoring for HCC is required for individuals who already had
cirrhosis at the time of clearance of the HCV.
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